These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis. Lin Z; Liu Y; Cai S; Yang C; Zhou L; Li W Technol Cancer Res Treat; 2021; 20():15330338211039131. PubMed ID: 34669528 [No Abstract] [Full Text] [Related]
7. KRAS Mutation Status Predicts Site-Specific Recurrence and Survival After Resection of Colorectal Liver Metastases Irrespective of Location of the Primary Lesion. Shindoh J; Nishioka Y; Yoshioka R; Sugawara T; Sakamoto Y; Hasegawa K; Hashimoto M; Kokudo N Ann Surg Oncol; 2016 Jun; 23(6):1890-6. PubMed ID: 26786089 [TBL] [Abstract][Full Text] [Related]
8. Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer. Jones RP; Sutton PA; Evans JP; Clifford R; McAvoy A; Lewis J; Rousseau A; Mountford R; McWhirter D; Malik HZ Br J Cancer; 2017 Mar; 116(7):923-929. PubMed ID: 28208157 [TBL] [Abstract][Full Text] [Related]
9. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis. Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246 [TBL] [Abstract][Full Text] [Related]
10. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. Umeda Y; Nagasaka T; Mori Y; Sadamori H; Sun DS; Shinoura S; Yoshida R; Satoh D; Nobuoka D; Utsumi M; Yoshida K; Yagi T; Fujiwara T J Hepatobiliary Pancreat Sci; 2013 Feb; 20(2):223-33. PubMed ID: 23010994 [TBL] [Abstract][Full Text] [Related]
11. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Vauthey JN; Zimmitti G; Kopetz SE; Shindoh J; Chen SS; Andreou A; Curley SA; Aloia TA; Maru DM Ann Surg; 2013 Oct; 258(4):619-26; discussion 626-7. PubMed ID: 24018645 [TBL] [Abstract][Full Text] [Related]
12. Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. Tsilimigras DI; Ntanasis-Stathopoulos I; Bagante F; Moris D; Cloyd J; Spartalis E; Pawlik TM Surg Oncol; 2018 Jun; 27(2):280-288. PubMed ID: 29937183 [TBL] [Abstract][Full Text] [Related]
13. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases. Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703 [TBL] [Abstract][Full Text] [Related]
14. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. Teng HW; Huang YC; Lin JK; Chen WS; Lin TC; Jiang JK; Yen CC; Li AF; Wang HW; Chang SC; Lan YT; Lin CC; Wang HS; Yang SH J Surg Oncol; 2012 Aug; 106(2):123-9. PubMed ID: 22331825 [TBL] [Abstract][Full Text] [Related]
15. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Karagkounis G; Torbenson MS; Daniel HD; Azad NS; Diaz LA; Donehower RC; Hirose K; Ahuja N; Pawlik TM; Choti MA Cancer; 2013 Dec; 119(23):4137-44. PubMed ID: 24104864 [TBL] [Abstract][Full Text] [Related]
16. Prognostic Implication of KRAS Status after Hepatectomy for Colorectal Liver Metastases Varies According to Primary Colorectal Tumor Location. Sasaki K; Margonis GA; Wilson A; Kim Y; Buettner S; Andreatos N; Gani F; Amini N; Spolverato G; Pawlik TM Ann Surg Oncol; 2016 Oct; 23(11):3736-3743. PubMed ID: 27352204 [TBL] [Abstract][Full Text] [Related]
17. The prognostic impact of KRAS, its codon and amino acid specific mutations, on survival in resected stage I lung adenocarcinoma. Izar B; Zhou H; Heist RS; Azzoli CG; Muzikansky A; Scribner EE; Bernardo LA; Dias-Santagata D; Iafrate AJ; Lanuti M J Thorac Oncol; 2014 Sep; 9(9):1363-9. PubMed ID: 25122432 [TBL] [Abstract][Full Text] [Related]
18. KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib. Smith JC; Brooks L; Hoff PM; McWalter G; Dearden S; Morgan SR; Wilson D; Robertson JD; Jürgensmeier JM Eur J Cancer; 2013 Jul; 49(10):2424-32. PubMed ID: 23510802 [TBL] [Abstract][Full Text] [Related]
19. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Schirripa M; Cremolini C; Loupakis F; Morvillo M; Bergamo F; Zoratto F; Salvatore L; Antoniotti C; Marmorino F; Sensi E; Lupi C; Fontanini G; De Gregorio V; Giannini R; Basolo F; Masi G; Falcone A Int J Cancer; 2015 Jan; 136(1):83-90. PubMed ID: 24806288 [TBL] [Abstract][Full Text] [Related]
20. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]